cagrilintide and semaglutide 2.4 mg Efficacy safety of co-administered once-weekly 2·4 with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial 1 CagriSema 2.4 mg /

Your weight plateau between 116-118 kg despite severe appetite suppression is likely due to gastric emptying tachyphylaxis, metabolic adaptation, and insuffi...

This paper advances a testable hypothesis: reductions in food noise may shift the balance of activity among DMN, salience, and executive networks in ways that support more adaptive forms of prospection

15-20% body weight reduction

Learn what to expect and how to manage symptoms.

But Serena Williamss revelation signals a potential cultural shift - are we moving into an era where science, and not sweat alone, drives results?

Harnessing the power of clinically proven natural botanicals, Perimenopause Support and Metabolism Ignite work together by regulating estrogen levels and switching on energy burn to supercharge weight loss